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Background Second lung primaries occur at a rate of2% per patient per year after cura-
tive resection for non-small cell lung carcinoma (NSCLC). The aim of this study was to
evaluate the role of fluorescence bronchoscopy using the Xillix(R) LIFE-Lung Fluorescent
Endoscopy SystemTM (LIFE-Lung system) in the surveillance of patients for second
NSCLC primaries after resection or curative photodynamic therapy (PDT).
Methods NSCLC patients who were disease-free following resection or endobronchial
PDT were identified and recruited to participate in a LIFE bronchoscopy surveillance
program. All suspicious areas were biopsied; areas of apparent normal mucosa served as
negative controls. Biopsy specimens were reviewed by a single pulmonary pathologist.
Results Thirty-six patients underwent 53 surveillance LIFE bronchoscopies and 6]
112 biopsies revealed intraepithelial neoplasia (IEN) or invasive carcinoma in 6/36
(17%) of patients. The overall relative sensitivity of LIFE versus conventional bronchos-
copy was 165% with a negative predictive value of 0.96, for the post-resection subset of
patients these values increased to 200% and 0.97, respectively.
Conclusions Surveillance LIFE bronchoscopy identified intraepithelial or invasive le-
sions in 17% of patients previously thought to be disease-free. These data support future
multicenter trials on fluorescence bronchoscopic surveillance of NSCLC patients after
curative surgical resection or PDT.
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INTRODUCTION
Only about 14% of patients with invasive lung
cancer can be cured using conventional treatment
modalities (surgery, chemotherapy and/or radia-
tion therapy) [1]. By the time a carcinoma ofthe lung
produces symptoms and is diagnosed, it has usually
progressed locally beyond resectability (Stage IIIB)
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or metastasized (Stage IV). At present, only one out
of eight people diagnosed with non-small cell lung
carcinoma (NSCLC) is alive at five years. The only
way to significantly impact on the high mortality
from lung cancer appears to be identification of the
disease at an earlier stage, prior to its becoming a
systemic disease.
The histological response of the respiratory
mucosa to exogenous environmental stresses is
a predictable progression from normal mucosa
through metaplasia, dysplasia, carcinoma in situ
(CIS) and eventually resulting in invasive carcinoma
[2]. On an average, a period of four to five years
exists during which time individuals exfoliate mar-
kedly atypical cells into bronchial secretions that
antedates the progression to an invasive tracheo-
bronchial carcinoma [3]. During this exfoliative
period, the tracheobronchial trees of these indivi-
duals may harbor occult intraepithelial neoplasias
(IENs) below the resolution of conventional bron-
choscopy but potentially detectable by fluorescent
bronchoscopy.
Currently, lung carcinomas in high-risk patients
are most commonly identified through periodic
sputum cytologic analysis and/or standard chest
X-rays. Both of these methodologies are less than
optimum screening modalities; the former does not
localize the lesion within the tracheobronchial tree
and the latter is neither sensitive nor specific for the
malignancy.
Conventional white light bronchoscopy (WLB)
is thought by many to be a useful tool in localizing
radiographically occult NSCLCs in the tracheo-
bronchial tree. In actuality, only 29% of CISs and
69% of microinvasive tumors are identified endos-
copically with WLB even by experienced bron-
choscopists [4]. Early NSCLCs and even IENs are
detectable with a highly sensitive, relatively new
method of bronchoscopy that utilizes a blue light
to induce autofluorescence of the bronchial sur-
face; the Xillix(R) LIFE-Lung Fluorescent Endo-
scopy SystemTM.
In 1996 the LIFE-Lung system, an autofluo-
rescent tracheobronchial imaging system developed
by the British Columbia Cancer Research Centre in
conjunction with Xillix Technologies, was approved
by the Food and Drug Administration (FDA).
LIFE-Lung utilizes a helium-cadmium laser to
generate monochromatic blue (442 nm) light and
induce autofluorescence of the bronchial mucosa,
capitalizingonthe factthatthenormalandabnormal
tissues have different patterns of autofluorescence.
In vivo spectroscopy, with an optical multichannel
analyzer, enables the LIFE-Lung system to identify
dysplasia, CIS and microinvasive carcinomas. The
different autofluorescence patterns characteristic of
IENs and early, invasive carcinomas are detectable
by the LIFE-Lung system in the absence of exog-
enous photosensitizers [5].
The LIFE-Lung system is comprised ofa 125mW
helium-cadmium laser as a source of blue light
(442 nm), two image-intensified CCD cameras with
red and green filters, computer and a color video
monitor [6]. Blue light is delivered to the bronchial
surface via a standard, Olympus BF20 broncho-
scope. Non-collimated light (12-15mW) is emitted
from the distal end of the bronchoscope. Tracheo-
bronchial mucosal and submucosal fluorescence
in both the red (> 630 nm) and the green (520 nm)
spectra are simultaneously captured, integrated
and displayed in near real time on a color video
monitor.
In a normal bronchus, the predominant source of
fluorescence is the submucosa [6]. Several theories
exist as to the etiology of the diminished autofluo-
rescence of areas of dysplasia, CIS and invasive
carcinoma. Morphologic properties may explain
these differences in autofluorescence, i.e. they may
merely be a consequence of the thickening of the
abnormal epithelium or an increase in the bronchial
capillary density of IENs and invasive carcinomas.
Alternatively, a loss of natural fluorophors as
lesions progress from normal to malignant pheno-
type may be responsible for the differences in their
autofluorescence properties.
The aim of the current IRB approved LIFE
Bronchoscopy Surveillance Program for NSCLC
patients at the University of Pittsburgh Medical
Center is to determine the efficacy of the LIFE-
Lung imaging system in the surveillance of bothLIFE BRONCHOSCOPIC SURVEILLANCE 3
post-resection patients and photodynamic therapy
(PDT) patients treated with curative intent.
The largest subset ofpatients, those withNSCLC
who have undergone a prior complete surgical
resection and remain disease-free, are identified
from the Summit(R) database used by the University
of Pittsburgh, Section of Thoracic Surgery. This
database is collected prospectively and includes
all patients treated by the Section of Thoracic
Surgery at the University of Pittsburgh. Post-
resection patients are contacted and their disease
status verified. If eligible, they are offered a
surveillance LIFE bronchoscopic exam.
The second population of patients offered LIFE
surveillance at the University of Pittsburgh were
those with early and/or proximal NSCLCs (T0-
1NOM0) treated curatively with PDT identified
from a separate, prospectively collected database.
LIFE-bronchoscopy was performed 6 weeks
post-tracheobronchial PDT treatment to re-evalu-
ate the treated mucosa and to guide biopsies of
any suspicious areas that might represent persistent
and/or recurrent disease. Biopsies were performed
at all sites previously treated with PDT, even if the
mucosa appeared normal, to confirm complete his-
tologic eradication of all lesions.
The standard interval between PDT treatments
with curative intent at our institution is between 4
and 6 weeks. We opted to perform a LIFE exam
at that time, recognizing that the specificity of the
LIFE bronchoscopic exam post-PDT might be
lower than previously reported by Lam et al. [7]
due to the retained Photofrin IITM. We accepted the
potentially higher number offalse positives detected
by LIFE because delaying the exam beyond 6 weeks
post-PDT (to allow for further clearance of Photo-
frin II) could compromise patient care if additional
PDT was required.
All surveillance LIFE bronchoscopicexams were
conducted as outpatient procedures using intra-
venous conscious sedation. Aerosolized and viscous
1% lidocaine, as well as cetacaine spray, were
employed to achieve topical anesthesia of the oro-
and hypopharynx. Lidocaine (1%) was instilled on
the vocal cords and intratracheally, as needed, to
maintain adequate topical anesthesia during the
exam. Patient sedation and amnesia were achieved
with intravenous versed and fentanyl.
Conventional WLB was carried out first using
an Olympus BF20DTM fiberoptic bronchoscope.
The entire tracheobronchial tree was inspected, the
exam was videotaped and images were taken ofany
abnormalities. Lesions were classified clinically into
three categories according to the clinical classifi-
cation system first described by Lam et al. [7]. On
white light exam normal mucosa was classified as
Class I; areas with non-specific erythema, swelling
or thickening ofthe mucosa, trauma, anatomic ano-
malies or granulation tissue were classified as Class
II; and areas or nodularity, mucosal irregularity
or focal thickening were classified as Class III
(Fig. l(a)). On LIFE exam, bright green areas
represent normal mucosa and were defined as
Class I (Fig. (b) and Fig. 2); slightly brown lesions
with ill-defined margins were classified as Class II
and definite brown or reddish-brown lesions with
discrete borders were designated as Class III
(Fig. 3).
The exact locations of all Class II and Class III
changes were recorded on video and in the image
management program of the LIFE system to afford
retrieval to facilitate future examinations. Fluores-
cence bronchoscopywas performed using the LIFE-
Lung system following completion of the WLB by
changing to the helium-cadmium light source and
connecting the LIFE camera. Once LIFE broncho-
scopy has begun revisions were not permitted to the
classifications assigned to mucosal lesions during
the precedingWLB. All Class II and Class III lesions
were biopsied and random biopsies were obtained
from visually (by both WLB and LIFE) normal
mucosa.
PDT using PhotofrinTM( 1.5 mg/kg) delivering
an energy dose of 100-200J/cm over 250-500s
was performed on all areas of histologically-con-
firmed CIS or microinvasive cancer identified by
eitherWLB or LIFE exam. A "clean-up" WLB was
performed on post-operative day one following
PDT to debride/remove obstructing, tumor-muco-
sal casts.4 T.L. WEIGEL et al.
FIGURE 2 Normal LIFE exam image (Class I) of left upper
lobe lingula showing bright green areas of normal mucosa.
FIGURE (a) Class II WLB image. (b) Corresponding
Class LIFE image of biopsy proven overlying benign sub-
mucosal nodule.
CIS and microinvasive lesions treated with PDT
were re-examined with both WLB and LIFE
bronchoscopy at four months post-PDT to deter-
mine the durability of response. Additional PDT
and/or surgical resection was performed if there
was histologic evidence of recurrence or persistence
FIGURE 3 Class III LIFE image of right upper lobe show-
ing definite reddish-brown areas with discrete borders.
of severe dysplasia and/or progression to an inva-
sive carcinoma. All pathologic evaluations of the
mucosal biopsies were made without knowledge of
bronchoscopic findings.LIFE BRONCHOSCOPIC SURVEILLANCE 5
RESULTS
Over the twelve-month period from 12/97 to 12/98
a total of 36 patients underwent 53 surveillance
LIFE exams (Table I). Thirty-four patients who
were status-post-complete resection of a NSCLC
underwent 46 surveillance LIFE exams. Ofthis 82%
(28/34) ofthe patients had early stage disease (Stage
I or II); the remaining six patients (18%) had Stage
IIIA NSCLC. An IEN or invasive carcinoma was
identified in 5/34 (15%) of the post-resection
patients screened. The addition of the LIFE exam
to conventionalWLB increased the overall sensitiv-
ity ofpost-operative screening from 33% to 66%. In
the post-surgical population of patients, the rela-
tive overall sensitivity of LIFE versus WLB was
200%. LIFE bronchoscopy correctly identified
2/3 (67%) of the IENs versus 0/3 (0%) for WLB.
The negative predictive value of LIFE bronchos-
copy in post-resection patients was 0.97 (Table II).
We performed 11 LIFE exams on five patients
that were status-post-PDT with curative intent.
Three of these patients also had a resection of a
separate NSCLC primary. Eight lesions were
identified in these five patients (one patient had
four separate lesions) treated definitively with nine
courses of PDT: two patients required one course,
two patients required two courses and one patient
TABLE Demographics and disease status post-curative re-
section or PDT (n 36)
Gender Male 22
Age Average 65
Histology NSCLC 35
Adenocarcinoma 14
Squamous cell 19
Poorly differentiated 2
Treatment Surgery 34
Wedge resection 3
Lobectomy 24
Lingulectomy
Pneumonectomy 3
Surgery plus PDT 3
Stage IA 6
(resection IB 14
patients) IIA 4
IIB 4
IIIA 6
Female 14
Range 42-84
SCLC
PDT only 2
required three courses to eradicate all histologic
disease.
Only one lesion was detected in the post-PDT
subset of patients and it was detected by both LIFE
andWLB. No IENs were identified in the post-PDT
subset of patients (Table III).
DISCUSSION
In 1998 over 160,000 individuals died of lung can-
cer in the United States alone, exceeding the total
mortality from breast, prostate, pancreatic and
all lymphomas and leukemias. Much controversy
exists with respect to the current practice and future
standard ofcare with respect to screening for breast,
colon and prostrate cancer [8]. "Virtually all orga-
nizations, however, concur that screening for lung
cancer is not justified.., the American College of
TABLE II Detection with LIFE versus WLB post-resection
patients (n 89 evaluable biopsies)*
WLB LIFE
True positive 2 4
False negative 4 2
True negative 72 40
False positive 11 43
IEN+ invasive carcinoma
Sensitivity 0.33 0.66
Specificity 0.86 0.48
IEN only
Sensitivity 0.00 0.66
Specificity 0.86 0.48
*Results of a per lesion analysis.
TABLE III Detection with LIFE versus WLB Post-PDT
patients (n 35 evaluable biopsies)*
WLB LIFE
True positive
False negative 0 0
True negative 33 9
False positive 25
IEN+ invasive carcinoma
Sensitivity 1.0 1.0
Specificity 0.97 0.26
*Results of a per lesion analysis.6 T.L. WEIGEL et al.
Surgeons, American College of Radiology, the Na-
tional Cancer Institute, the US Preventive Services
Task Force and the Canadian Task Force on the
Periodic Health Examination all decline to recom-
mend lung cancer screening with any test at any
frequency" [9]. A recent critical review of 10 pros-
pective trials on screening for lung cancer by Strauss
et al. including four randomized controlled trials,
two non-randomized controlled trials and four un-
controlled trials failed to show a reduction in lung
cancer mortality between the experimental and con-
trol populations in the six controlled trials [10].
The efficacy of screening for second lung cancer
primaries in the subset of high-risk patients with a
history of prior NSCLC is unknown. In addition,
technological advances in both the diagnosis and the
treatment ofearly tracheobronchial mucosal lesions
render the conclusions drawn from prior trials of
historical significance only.
In March 1998 Lam et al. [7] published data from
the multi-institutional clinical study that showed
that the LIFE-Lung system, when used as an ad-
junct to conventional WLB, improved the physi-
cian’s ability to identify moderate/severe dysplasia
or worse. In this trial the efficacy of fluorescence
bronchoscopy in patients with suspected or proven
NSCLC was assessed: 154 of the 173 patients in this
trial were suspected ofhaving orknown to have lung
cancer based on symptoms and/or abnormal chest
radiograph (114 patients), abnormal sputum cytol-
ogy (29 patients) and 11 patients were known to
have lung cancer based on prior investigations. The
relative sensitivity ofLIFE versusWLB for invasive
carcinomawas only 1.46 (95% CI, 1.21-1.95) in this
trial. However, LIFE-Lung’s superiority in detect-
ing early, intraepithelial lesions was evident in this
trial. One hundred and two intraepithelial neo-
plasias were identified with 57 lesions diagnosed
on the LIFE-Lung examination versus only nine
lesions byWLB alone. Thus, the relative sensitivity
for LIFE versusWLB for intraepithelial neoplasias
in this trial was 6.3 (95% CI, 3.6-12.3).
AtUPMC, we are utilizing the LIFE-Lung system
as a surveillance tool in post-resection patients who
have had a curative resection or definitivePDT for a
NSCLC and are believed to be disease-free. The risk
of developing second lung primaries for patients
who have undergone potentially curative resections
of a NSCLC is 1-3% per patient per year. The
North American Lung Cancer Study Group
(NLCSG) documented a 3.6% per patient per year
risk of developing local recurrence and/or second
lung primaries in patients with NSCLC [11]. Data
from the Mayo Clinic on patients that underwent
surgical resection for sputum cytology positive,
roentenographically occult, lung cancers suggested
that second primary lung cancers occurred at a rate
as high as 5% per patient per year [12]. A recent
collective review of 1406 patients with occult or
stage I completely resected lung carcinomas
reported an incidence of second primary lung
cancers of 11.4% (range 3-30%) [1].
Patients who develop second primaries and/or
local recurrence have limited curative treatment
options because of their diminished pulmonary re-
serve as a consequence of their prior resection [13].
The peri-operative mortality for second primary
lung carcinomas is significantly higher than for the
first tumor and surgical options are both more
limited and more complicated as a consequence of
the re-operative nature of a second surgical ap-
proach 13]. In January 1998, however, the Federal
Drug Administration approved PDT as a curative
treatment modality for early (T1N0), NSCLCs in
patients that were poor candidates for surgery
and/or radiation therapy. Cortese et al. treated 21
patients with 23 early NSCLCs with curative intent
and documented a greater than 90% complete re-
sponse rate to PDT. In this series, 43% of the pa-
tients were spared surgery at 68 months follow-up
[12]. The LIFE-Lung system potentially affords the
physician the ability to detect, with a higher sensi-
tivity, early stage lesions that may be amenable to
definitive PDT. To date, we have treated eight
lesions with PDT with curtive intent.
We are currentl performing a LIFE exam to
delineate the exact site of the previously treated
lesion. However, in our series 25 of the biopsies
at the prior PDT treatment site were false positive
on LIFE exam (Table III). We speculate that this
may be secondary to retained photofrin in these
patients (Fig. 4). We are routinely performing LIFELIFE BRONCHOSCOPIC SURVEILLANCE 7
imens from these pre-malignant lesions may help
unravel the cascade ofmolecular events that occur in
tracheobronchial mucosa carcinogenesis. Identifi-
cation ofearly molecular markers may facilitate the
development of efficient, molecular sputum screen-
ing techniques for NSCLC as an adjunct to, and/or
replacement for traditional, costly, labor-intense
cytologic screening methods.
The Xillix (R) LIFE-Lung Fluorescent Endoscopy
System is a registered trademark of Xillix Technol-
ogies Corporation of Richmond, B.C., Canada.
FIGURE 4 Class III LIFE image of the trifurcation of right
upper lobe subsegments in a post-PDT patient. The reddish-
brown area was biopsy negative.
at one and three months post-PDT to re-biopsy the
former lesion to monitor for recurrent or persistent
disease.
CONCLUSIONS AND FUTURE
DIRECTIONS
Early detection and careful mapping ofpre-invasive
lesions with the Xillix LIFE-Lung systemmay trans-
late into improved survival of high-risk patients
such as post-resection and post-curative PDT
patients. The LIFE-Lung systemcan identify lesions
at an early stage, when they are potentially curable
with minimally invasive, therapeautic interventions
such as PDT. In addition, longitudinal monitoring
of IENs and PDT treated lesions with LIFE bron-
choscopy may help to better define their natural
history.
The current paradigm of lung carcinogenesis
depicts a multistage process with potential genetic
markers at each stage [14]. LIFE bonchoscopy
affords investigators the opportunity to identify
early mucosal abnormalities prior to the phenoty-
pic expression of a transformed cell, i.e. before the
development ofan invasive carcinoma. Biopsy spec-
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